|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Daniel P. O'Day||Chairman & CEO||7,27M||S.O.||1964|
|Mr. Andrew D. Dickinson||Executive VP & CFO||2,94M||S.O.||1970|
|Ms. Deborah H. Telman||Executive VP of Corporate Affairs, General Counsel & Corporate Secretary||2,32M||S.O.||1965|
|Ms. Johanna Mercier||Chief Commercial Officer||3,32M||S.O.||1970|
|Dr. Merdad V. Parsey M.D., Ph.D.||Chief Medical Officer||3,07M||S.O.||1963|
|Ms. Sandra Patterson||Senior VP, Corporate Controller & Principal Accounting Officer||S.O.||S.O.||1967|
|Ms. Jacquie Ross C.F.A.||Vice President of Investor Relations||S.O.||S.O.||S.O.|
|Ms. Jyoti K. Mehra||Executive Vice President of Human Resources||S.O.||S.O.||1976|
|Dr. Linda Slanec Higgins Ph.D.||Senior Vice President of Research, Innovation & Portfolio||S.O.||S.O.||1962|
|Dr. Rudolf Ertl||Senior Vice President of Commercial Operations of Australia, Canada, Europe||S.O.||S.O.||1946|
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
L’ISS Governance QualityScore de Gilead Sciences, Inc. en date du 1 décembre 2023 est 1. Les scores principaux sont Audit : 3; Société : 4; Droits des actionnaires : 1; Compensation : 3.